scholarly journals Hyperkalemic Recurrent Bilateral Lower Extremity Weakness in a Patient on Hemodialysis

2012 ◽  
Vol 2012 ◽  
pp. 1-3
Author(s):  
Getaw Worku Hassen ◽  
Suzanne Newstead ◽  
Lorraine Maria Giordano
Keyword(s):  
Lower Extremity ◽  
Renal Disease ◽  
Neurological Deficit ◽  
End Stage Renal Disease ◽  
Focal Neurological Deficit ◽  
Lower Extremity Weakness ◽  
Electrolyte Disorder ◽  
Life Threatening ◽  
Stage Renal Disease ◽  
End Stage

Hyperkalemia is a severe life-threatening electrolyte disorder that commonly affects the cardiac conductivity and contractility. Ascending paralysis affecting the extremities with focal neurological deficit as well as quadriparesis and a seizure associated with hyperkalemia has been reported in the literature. Here, we describe a case of isolated recurrent lower extremity paralysis and an episode of seizure in an 83-year-old patient with end-stage renal disease on hemodialysis.

scholarly journals Ifosfamide May Be Safely Used in Patients with End Stage Renal Disease on Hemodialysis

Sarcoma ◽  
2009 ◽  
Vol 2009 ◽  
pp. 1-5 ◽  
Author(s):  
Sheron Latcha ◽  
Robert G. Maki ◽  
Gary K. Schwartz ◽  
Carlos D. Flombaum
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Response To Therapy ◽  
Common Side Effect ◽  
Pharmacokinetic Data ◽  
Life Threatening ◽  
Stage Renal Disease ◽  
End Stage ◽  
Metastatic Sarcoma ◽  
Radiographic Improvement

Background. Pharmacokinetic data on clearance of ifosfamide in hemodialysis patients are limited. Consequently, these patients are excluded from therapy with this agent. We review the outcomes for patients at our institution with end stage renal disease on dialysis who received ifosfamide for metastatic sarcoma.Patients and Methods. We treated three patients with end stage renal disease on hemodialysis with escalating doses of ifosfamide. Data on radiographic response to therapy, WBC and platelet counts, signs or symptoms of infection, neuropathy and bladder toxicity are reported. Starting doses of ifosfamide were based on review of the literature available with subsequent modifications based on each patient's prior exposure to myelosuppressive agents and on symptoms of neurotoxicity and the degree of myelosuppression following each cycle of chemotherapy.Results. Myelosuppression was the most common side effect from therapy, but no patient developed a life threatening infection, neurotoxicity, or hematuria. One patient developed epistaxis in the setting of thrombocytopenia while on warfarin therapy. All patients had clinical evidence for therapeutic response and two had documented radiographic improvement following ifosfamide administration.Conclusion. Ifosfamide can be used safely in combination with hemodialysis in patients with end stage renal disease.

Hemorrhage as a life-threatening complication after valve replacement in end-stage renal disease patients

2015 ◽  
Vol 63 (7) ◽  
pp. 386-394 ◽  
Author(s):  
Taro Nakatsu ◽  
Nobushige Tamura ◽  
Shigeki Yanagi ◽  
Shoichi Kyo ◽  
Takaaki Koshiji ◽  
...  
Keyword(s):  
Renal Disease ◽  
Valve Replacement ◽  
End Stage Renal Disease ◽  
Life Threatening ◽  
Life Threatening Complication ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Results of lower extremity amputations in patients with end-stage renal disease

1994 ◽  
Vol 20 (1) ◽  
pp. 14-19 ◽  
Author(s):  
Christos D. Dossa ◽  
Alexander D. Shepard ◽  
Aaron M. Amos ◽  
Warren L. Kupin ◽  
Daniel J. Reddy ◽  
...  
Keyword(s):  
Lower Extremity ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Vancomycin Induced Thrombocytopenia – Protracted Course in a Hemodialysis Patient

2019 ◽  
Vol 12 (3) ◽  
pp. 749-754 ◽  
Author(s):  
Nisha Elizabeth Ajit ◽  
Sindhu Priya Devarashetty ◽  
Samip Master
Keyword(s):  
Renal Disease ◽  
Renal Clearance ◽  
End Stage Renal Disease ◽  
Side Effect ◽  
Hemodialysis Patient ◽  
Treatment Modalities ◽  
Platelet Destruction ◽  
Life Threatening ◽  
Stage Renal Disease ◽  
End Stage

Vancomycin induced thrombocytopenia (VIT) is an uncommon side effect of vancomycin which can manifest from mild petechiae to life-threatening bleed. Decreased renal clearance of vancomycin results in prolonged thrombocytopenia by antibody-mediated platelet destruction in the presence of vancomycin. Improvement in thrombocytopenia is achieved with the elimination of vancomycin. We describe a patient with end stage renal disease who experienced a protracted course of thrombocytopenia from vancomycin. We illustrate the mechanism of thrombocytopenia and the treatment modalities used by us and those described in literature. VIT is an important differential in patients with thrombocytopenia admitted to the hospital.

scholarly journals Survival after major lower extremity amputation in patients with end-stage renal disease

2019 ◽  
Vol 70 (4) ◽  
pp. 1291-1298 ◽  
Author(s):  
Isibor Arhuidese ◽  
Besma Nejim ◽  
Eunice A. Aji ◽  
Joseph Canner ◽  
Mahmoud B. Malas
Keyword(s):  
Lower Extremity ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Lower Extremity Amputation ◽  
Stage Renal Disease ◽  
End Stage ◽  
Extremity Amputation

Is lower extremity revascularization worthwhile in patients with end-stage renal disease?

Surgery ◽  
2000 ◽  
Vol 128 (3) ◽  
pp. 472-479 ◽  
Author(s):  
Peter Korn ◽  
Stephen J. Hoenig ◽  
John J. Skillman ◽  
K.Craig Kent
Keyword(s):  
Lower Extremity ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Stage Renal Disease ◽  
End Stage ◽  
Lower Extremity Revascularization

Lower Extremity Bypass Procedures in Diabetic Patients with End-Stage Renal Disease: Is It Worthwhile?

2004 ◽  
Vol 99 (2) ◽  
pp. c37-c41 ◽  
Author(s):  
S. Georgopoulos ◽  
K. Filis ◽  
G. Vourliotakis ◽  
C. Bakoyannis ◽  
A. Papapetrou ◽  
...  
Keyword(s):  
Lower Extremity ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Diabetic Patients ◽  
Stage Renal Disease ◽  
End Stage
Sign in / Sign up

Export Citation Format

Share Document